MedTrace Logo

Effect of Korean Red Ginseng on Oxidation in Middle-aged and Elderly Sub-health Population

NCT05592093 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2026-01-21

No results posted yet for this study

Summary

The objective of this study is to examine the effects and safety of Korean red ginseng capsule and placebo with middle-aged and elderly sub-health population.

Conditions

  • Healthy Ageing
  • Antioxidative Stress

Interventions

DRUG

Korean red ginseng capsule (marketed product in Korea)

Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.

DRUG

Korean red ginseng capsule(placebo)

KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • Beijing Obstetrics and Gynecology Hospital

    collaborator OTHER

  • Foshan Fuxing Changcheng Hospital

    collaborator UNKNOWN

  • Nanchang Hongdu Hospital of TCM

    collaborator UNKNOWN

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Yaomin Hu, Professor · RenJi Hospital

  • Chenghong Yin, Professor · Beijing Obstetrics and Gynecology Hospital

  • Suzhen Wu, Professor · Foshan Fuxing Changcheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-10-30
Completion
2024-12-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05592093 on ClinicalTrials.gov